Daiichi Sankyo Co. Ltd., of Tokyo, said it received approval in Japan for anticoagulant Lixiana (edoxaban) for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for the treatment and recurrence prevention of venous thromboembolism, deep vein thrombosis and pulmonary thromboembolism.